Anzeige
❌
Mehr »
Dienstag, 20.10.2026 - Börsentäglich über 12.000 News
Breaking News: Neuentdeckung sorgt für Aufsehen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
257 Leser
Artikel bewerten:
(1)

Seed to Sale CBD Company Panacea Life Sciences, Inc. Announces Participation at White Label World Expo in Las Vegas

Company to showcase its proprietary vegan softgel manufacturing capabilities.

GOLDEN, CO / ACCESSWIRE / May 24, 2022 / Panacea Life Sciences Holdings, Inc. (OTCQB:PLSH) a Colorado, USA-based cannabinoid research and certified GMP manufacturing company, today announced that it will be attending the White Label World Expo in Las Vegas at the Convention Center from May 25-26, 2022. Panacea will be showcasing its broad capabilities live during the Expo at Booth #5038.

Panacea Life Sciences will be highlighting its newly acquired, proprietary vegan softgel capabilities as well as the launch of a new pet treat line. While Panacea's main focus is CBD manufacturing, the Company has the expertise and capabilities to perform contract manufacturing for the entire health and wellness industry for humans and companion animals, including cannabinoid products, nutraceuticals, and other high-end dietary supplements.

With specialties in softgel manufacturing, Panacea has the ability to produce 1.5M softgels per day and can also produce 10,000 liquid fills per day. The Company provides full-range services from R&D and custom formulation to manufacturing and fulfillment from its 51,000 square foot facility located in Golden, Colorado.

The White Label World Expo is billed as the premiere destination for thousands of global leaders, entrepreneurs, online sellers, retailers and distributors to come together with businesses, e-commerce providers and startup owners. Panacea Life Sciences is all ready to go and will be at booth #5038 on May 25th & May 26th from 10 am-5 pm.

More details about the show can be found at whitelabelexpo.com.

About Panacea Life Sciences Holdings, Inc.

Panacea Life Sciences Holdings, Inc. is a seed to sale cannabinoid manufacturer and research company that produces purposeful, natural medicine for consumers and pets. Panacea sells softgels, gummies, tinctures, sublingual tablets, cosmetics, and other topicals. If you would like more information about this topic or to learn more about Panacea and its products or our land-to-brand practices, please visit www.panacealife.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the effectiveness of CBD and other cannabinoids improving the lives of people and pets. You can identify forward-looking statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, risks arising from supply chain disruptions on our ability to obtain raw materials as well as similar problems with our vendors, the impact of the pandemic including new variants on the national and global economy, the impact on the Russian invasion of Ukraine on the global economy, lack of available funding at sufficient levels to meet our working capital needs, competition from third parties; intellectual property rights of third parties; regulatory constraints, including the need for FDA approval under certain circumstances; and changes in technology and methods of marketing; as well as those risks and uncertainties described by us in our annual report on Form 10-K for the fiscal year ended December 31, 2021 under the heading "Risk Factors". Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law.

Contact

Nick Cavarra
Nick.cavarra@panacealife.com

SOURCE: Panacea Life Sciences, Inc



View source version on accesswire.com:
https://www.accesswire.com/702463/Seed-to-Sale-CBD-Company-Panacea-Life-Sciences-Inc-PLSH-Announces-Participation-at-White-Label-World-Expo-in-Las-Vegas

© 2022 ACCESS Newswire
KI-Euphorie kippt - Bei diesen 5 Aktien droht der Crash!
Drei Jahre lang kannten KI-Aktien fast nur eine Richtung: nach oben. Billionenschwere Investitionspläne von Alphabet, Amazon, Meta und Microsoft haben Halbleiter- und Infrastrukturwerte auf immer neue Höhen getrieben. Doch jetzt bekommt die Erfolgsstory gefährliche Risse.

Steigende Anleiherenditen verteuern die Finanzierung, während die gewaltigen KI-Ausgaben zunehmend nicht mehr aus den laufenden Cashflows bezahlt werden können. Gleichzeitig zeigen günstigere chinesische Modelle, dass leistungsfähige KI womöglich mit deutlich weniger Rechenleistung auskommt. Damit wächst die Gefahr, dass heute für Milliarden errichtete Kapazitäten morgen nicht die erhofften Renditen liefern.

Für Anleger könnte das zum Problem werden. Denn treffen steigende Finanzierungskosten auf Überkapazitäten und enttäuschende Cashflows, geraten gerade hoch bewertete KI-Profiteure schnell unter Druck. Aus den größten Gewinnern der vergangenen Jahre könnten so die größten Verlierer der nächsten Korrektur werden.

In unserem aktuellen Spezialreport zeigen wir 5 Aktien, bei denen das Chance-Risiko-Verhältnis jetzt besonders gefährlich erscheint – und bei denen Anleger genauer hinschauen sollten.

Jetzt den kostenlosen Report sichern – bevor die KI-Euphorie ihren nächsten Realitätstest erlebt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.